Stockwinners Market Radar for February 05, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:04 EST Cathie Wood's ARK Investment bought 201K shares of Robinhood today

20:03 EST Cathie Wood's ARK Investment bought 62.1K shares of Tesla today

19:50 EST Sunworks trading halted, news pending

19:28 EST JFrog CEO sells $4.33M in common stock - In a regulatory filing, JFrog disclosed that its CEO Ben Shlomi sold 123.7K shares of common stock on February 2nd in a total transaction size of $4.33M.

18:02 EST Patterson-UTI reports average of 122 drilling rigs in U.S. in January - Patterson-UTI reported that for the month of January 2024, the company had an average of 122 drilling rigs operating in the United States.

17:39 EST Wolfspeed directors buy $767K in common stock - In regulatory filing, Wolfspeed disclosed that its directors Stacy Smith, John Replogle and Darren Jackson bought 9.5K, 10K and 10K shares of common stock on February 2nd in respective transactions of $249K, $260K, and $258K. Shares are up 1% afterhours at $25.57.

17:33 EST Coherent reports Q2 adjusted gross margin 36% - At the midpoint of company's 35%-37% guidance and a 120 bp sequential increase.

17:26 EST Pedevco receives approval in Colorado for Roth 2-11 OGDP - PEDEVCO announced that it received approval on January 31, from the Colorado Energy and Carbon Management Commission, or ECMC, of the Company's Roth 2-11 Oil and Gas Development Plan, or OGDP, which covers 2,560 acres and up to 11 horizontal Niobrara wells in Weld County, Colorado. The Company plans to commence drilling operations in Q2, with initial production anticipated in the second half of 2024.

17:20 EST Biofrontera announces FDA issued letter regarding sNDA for Ameluz - Biofrontera announced that the FDA has issued a "no filing review issues identified" letter regarding the sNDA, or supplementary New Drug Application submitted by its licensor Biofrontera Bioscience to increase the maximally approved dosage from one to three tubes of Ameluz per treatment. FDA has completed its filing review and will begin its substantive review of Biofrontera's communication. The sNDA is supported by two clinical phase I studies investigating the safety of the application of three tubes of Ameluz. The studies showed that after application of three tubes the blood concentrations of the active ingredient and the metabolite are transiently increased but they were several magnitudes below those at which side effects are known to occur. The systemic and application site adverse events were similar to those observed with one tube of Ameluz(R), with patients frequently experiencing a transient inflammatory response at the application site and pain during illumination that was managed by a cooling air stream.

17:05 EST Kroger CFO Millerchip to step down - Kroger announced that Gary Millerchip is stepping down as senior vice president and chief financial officer to assume an executive role at another public company. Todd Foley, group vice president, corporate controller and chief accounting officer, has been appointed interim chief financial officer, effective today. The Company will name a CFO successor at a later date. "Todd is a proven leader who has served in key finance roles and has contributed meaningfully to Kroger's growth and transformation over more than 20 years," said Rodney McMullen, Kroger's chairman and CEO. "Todd is the right person to take the helm and will step in seamlessly to continue advancing our value creation model and maintain a strong financial framework for our company as we plan ahead for our pending merger with Albertsons. At Kroger, we are fortunate to benefit from an incredibly deep bench of talent across our finance team and all levels of our organization as we continue to execute our strategy and generate sustainable returns for our shareholders."

17:01 EST Bit Digital produces 145.7 BTC in January, down 14% from prior month - Bit Digital announced its unaudited digital asset production and corporate updates for the month of January 2024. In January 2024, the company produced 145.7 BTC, a 14% decrease compared to the prior month. The company's active hash rate was approximately 2.50 EH/s as of January 31, 2024. Treasury holdings of BTC and ETH were 739.2 and 18,072.2 with a fair market value of approximately $31.4 million and $41.3 million, respectively, on January 31, 2024. The BTC equivalent of the company's digital asset holdings as of January 31, 2024, was approximately 1,739.0 or approximately $74.0 million. The company had cash and cash equivalents of $22.6 million as of January 31, 2024.

16:54 EST Natura &Co to assess potential separation of Natura &Co Latam, Avon - Natura &Co announced that its board of directors has authorized its management to assess a possible separation of Natura &Co Latam and Avon to unlock further shareholder value. A separation would result in two independent, publicly traded beauty companies Natura and Avon with independent governance and management teams. This assessment is consistent with Natura &Co's ongoing strategy of simplifying its corporate structure while providing increased autonomy to its business units and follows the recent divestments of Aesop and The Body Shop. Natura would continue to operate with both brands in the region, so the potential separation would not impact the integration of the brands in Latin America. In turn, Avon would indirectly benefit from the sales in Latin America through a commercial arrangement with Natura, while continuing its operations in other markets outside Latin America. The company said, "There can be no assurance that any separation will ultimately be recommended by the Board of Directors. Completion of a separation would be subject to various conditions, including final approval from the Board of Directors and consent from the majority of shareholders, among others."

16:50 EST Intevac says not providing Q1 revenue guidance - Says expects to end 2024 with similar cash position to 2023. Says experienced persistent delay in collections from large customer. Says expects Trio negotiations to be complete by this quarter. Says in the middle of negotiating a sales and purchase agreement.

16:39 EST Crown Holdings falls 11% to $78.75 after Q4 results, FY24 outlook miss estimates

16:37 EST NYSE suspends trading in Cano Health and begins delisting process - Cano Health announced that on February 5, the NYSE notified the Company that the NYSE had determined to commence proceedings to delist the Company's Class A common stock, par value $0.01 per share and immediately suspend trading in the Company's Common Stock pursuant to Section 802.01D of the NYSE Listed Company Manual after the Company filed voluntary petitions for relief under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware on February 4. The NYSE will apply to the SEC to delist the Company's Common Stock upon completion of all applicable procedures. The Company does not intend to appeal the NYSE's determination and therefore expects that its Common Stock will be delisted from the NYSE. The Common Stock is expected to continue trading on the OTC market under the symbol "CANOQ."

16:33 EST BetMGM's newly designed sports betting App launches in Nevada - BetMGM's newly designed mobile sports betting app is now live in Las Vegas. Powered by Entain, the newly designed BetMGM Nevada app offers sports fans significant enhancements to the mobile sports betting experience including an exponential increase in prop and parlay wager options, live streaming capabilities, digital deposits and withdrawals.

16:31 EST Cboe Global Markets reports January monthly trading volume statistics - Cboe Global Markets reported January monthly trading volume statistics across its global business lines. Reference Link

16:23 EST Illumina chief revenue officer Nadeem Ahmed departs - illumin announced that Nadeem Ahmed, chief revenue officer, is no longer with illumin. The company is in the process of identifying Ahmed's successor, and on an interim basis, his responsibilities will be assumed by Joe Ontman, the company's chief business development officer and co-founder.

16:19 EST Rigetti Computing awarded SBRI grant funded by NQCC for quantum computer - Rigetti was awarded a Small Business Research Initiative SBRI grant delivered SBRI grant and funded by the National Quantum Computing Centre NQCC to develop and deliver a quantum computer to the NQCC. Rigetti proposes to deploy a 24-qubit quantum computer based on the Company's fourth generation Ankaa class architecture. The system will be deployed at NQCC's Harwell Campus, which is due to open in 2024 and will serve as NQCC's landmark facility to support world-class quantum computing research in the UK. The proposed system will feature the hallmarks of Rigetti's recently launched 84-qubit Ankaa-2 system, including tunable couplers and a square lattice. This new chip architecture enables faster gate times, higher fidelity, and greater connectivity compared to Rigetti's previous generations of quantum processing units QPUs The Ankaa-2 system has achieved a 98% median 2-qubit fidelity, a 2.5x improvement in error performance compared to the Company's previous QPUs, and a 2-qubit gate time of 68 nanoseconds - the shortest gate time demonstrated by a Rigetti QPU.

16:19 EST Amkor Technology down 6% at $30.24 after Q4 results, below-consensus guidance

16:17 EST Two Harbors CFO Riskey to retire - Two Harbors Investment Corp. announced that Mary Riskey intends to retire from her position as Vice President and Chief Financial Officer of the company. Two Harbors has initiated an external search for a new Chief Financial Officer, and Ms. Riskey plans to continue to serve in her role through August 1, 2024, or until a successor is appointed by the company. "I would like to thank Mary for her many years of unwavering commitment, dedicated service, and outstanding contributions to Two Harbors," stated Bill Greenberg, Two Harbors' President and Chief Executive Officer. "She has been instrumental in our evolution over the years, and will leave an indelible mark on our organization. As Mary embarks on a well-deserved retirement, I want to express my deep gratitude and wish her much happiness in the next chapter of her life."

16:14 EST Nexstar adopts policy regarding roles of chair and CEO - Nexstar Media Group announced that its Board of Directors has adopted a policy regarding the roles of Chairperson of the Board of Directors and Chief Executive Officer. Under the policy, the roles of Chairperson of the Board of Directors and Chief Executive Officer of the Company may not be held by the same individual. The new policy will take effect only after Nexstar's Founder, Chairman, and Chief Executive Officer Perry Sook leaves the Company and the Board. Mr. Sook's current employment agreement with Nexstar runs through March 31, 2026, and as of September 30, 2023, he is the Company's third largest shareholder, with holdings of approximately 4.6% of its outstanding shares. The Board believes the adoption of this policy is in the best interests of the Company and its shareholders, as the new policy does not interfere with Mr. Sook's continued leadership of Nexstar and the benefits he brings to the Company, while establishing a plan that provides a runway for the most qualified individuals to serve as Chief Executive Officer and Chairperson in the future.

16:10 EST Datadog names Sara Varni as new Chief Marketing Officer - Datadog (DDOG) announced that Sara Varni is joining as Chief Marketing Officer, effective immediately. Varni brings more than 15 years of marketing experience centered around enterprise software products-including leadership positions at Attentive, Twilio (TWLO) and Salesforce (CRM) to her role at Datadog. Varni was most recently CMO at Attentive.

16:08 EST Chegg names David Longo CFO - Chegg announced the appointment of David Longo as Chief Financial Officer, effective February 21. Longo currently serves as Vice President, Chief Accounting Officer, Corporate Controller, and Assistant Treasurer at Chegg. He will succeed Andrew Brown, who announced his retirement in the fall of last year, after more than 12 years at Chegg. "David is the perfect candidate to take on the CFO role and I couldn't be more confident in his ability to drive growth and shareholder value," said Dan Rosensweig, CEO and President of Chegg. "David's dynamic and forward-thinking leadership has already played a key role in advancing Chegg's mission of harnessing AI to improve student outcomes." Rosensweig added, "I also want to thank Andy Brown for his innumerable contributions to Chegg over the past 12 years. Andy played a key role in transforming Chegg into the leading student-first connected learning platform. We are deeply grateful for his financial stewardship over the years and wish him all the best in his retirement."

16:05 EST Weave names David McNeil as Chief Revenue Officer - Weave "announced the appointment of David McNeil as Chief Revenue Officer. McNeil will bring his expertise in scaling SaaS businesses to lead Weave's sales, customer success, revenue operations, and payments teams. McNeil brings over 25 years of experience in SaaS, payments, go-to-market strategy, and strategic partnerships. He spent six years at HubSpot, where he was instrumental in leading sales teams as the company grew from $90M in annual recurring revenue to over $990M."

16:03 EST Kaixin Auto gets Nasdaq letter regarding minimum bid rule - Kaixin Auto Holdings announced the receipt of a notification dated February 1 from the Listing Qualifications department of the Nasdaq Stock Marke notifying Kaixin that, for the 30 consecutive business days ended January 31 the Company failed to meet the requirement of maintaining a minimum bid price of $1 per share pursuant to Nasdaq Rule 5550(a)(2). The Nasdaq Letter does not impact the Company's listing on the Nasdaq Capital Market at this time. In accordance with Nasdaq Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until July 30, to regain compliance with the Rule. If, at any time before July 30, the closing bid price of the Company's common stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will inform the Company that the Company has regained compliance with the Rule.

16:02 EST Exicure, Bluejay Therapeutics enter into patent license pact - Exicure and Bluejay Therapeutics announced they entered into a patent license agreement to develop cavrotolimod for potential treatment for hepatitis. Under the terms of the agreement, Bluejay will receive an exclusive license in the field of hepatitis to all of Exicure's relevant patents. Bluejay paid Exicure an initial small, one-time payment after the execution of this Agreement. Exicure will also be entitled to modest royalties on future net sales on all licensed technology by Bluejay during the term of the licensed patents. Exicure will be responsible for, and make all decisions concerning, the preparation, filing, prosecution, and maintenance for each patent and patent application included within the licensed patents.

15:44 EST Bit Origin Ltd trading resumes

15:15 EST Microsoft Gaming CEO says company planning business update event for next week - Microsoft Gaming CEO Phil Spencer said in a post on X, formerly Twitter, "We're listening and we hear you. We've been planning a business update event for next week, where we look forward to sharing more details with you about our vision for the future of Xbox. Stay tuned." Reference Link

14:35 EST Allegiant Travel says 2024 focus will be on optimization - Allegiant Travel stated: "Although we are proud of our performance in 2023, 2024 will continue our focus on restoring peak-period utilization, thereby bolstering our financial performance through increased margins. In the coming months we expect to induct our first Boeing MAX aircraft. We have tempered capacity growth to roughly five percent to ensure a smooth integration. The addition of this aircraft will improve operational reliability, enhance the customer experience, and deliver improved economics. In 2024, our focus will be on optimization. With continued focus on a number of long-term initiatives, we expect to see planned improvements throughout the business. I remain confident we will continue our operational excellence, a necessity for continued financial success. Our team members' efforts and dedication are the reasons for our 2023 industry leading performance. Team Allegiant remains the best in the industry."

14:30 EST La-Z-Boy announces investment in furniture market showrooms - La-Z-Boy Incorporated announced its investment and ongoing support of key industry furniture markets. La-Z-Boy Incorporated is formally extending the lease for its portfolio of showrooms at High Point Market in Furniture Plaza, High Point, NC and Las Vegas Market, B555 at World Market Center Las Vegas, NV. La-Z-Boy is also committing to major renovations of its showrooms in High Point, including showrooms for the La-Z-Boy brand, La-Z-Boy International, and England Furniture. These investments will allow La-Z-Boy Incorporated to better serve its customers, partners, and all stakeholders. "Our commitment today is wholly enabled by the continued market success and financial stability of La-Z-Boy Incorporated - even in the face of challenging industry and economic conditions," said Melinda D. Whittington, President and Chief Executive Officer of La-Z-Boy Incorporated. "These investments demonstrate our commitment to the industry furniture markets, while reimagining the showrooms where our brands come to life, as we meet our customers and demonstrate our product quality, comfort, and style."

13:02 EST Archer Daniels down 4% after Bloomberg report of DOJ accounting probe

12:33 EST Frontier executing formal review process to unlock shareholder value - Frontier Communications said earlier today in a press release, "As Frontier enters the next phase of its evolution, we believe that there are opportunities to create additional value for our shareholders. Accordingly, the Board and management team are executing a formal and comprehensive review process of all opportunities to unlock shareholder value, including continued optimization of our operational and financing strategy, strategic partnerships, joint ventures, divestitures, mergers, and business combinations. We appreciate the constructive and helpful input from our shareholders and look forward to providing updates on our progress as we execute our plan."

12:30 EST Jana Partners supports Frontier Communications review process - Jana Partners, a shareholder of Frontier Communications, issued a statement regarding Frontier's announcement that its board and management team are executing a formal and comprehensive review process of all opportunities to unlock shareholder value. "We are enthusiastic about Frontier's continued business momentum and potential for shareholders. We support the Company's focus and review of all opportunities to unlock shareholder value - and are confident in the Board and management team's ability to do so."

12:00 EST Catalent rises 9.6% - Catalent is up 9.6%, or $5.22 to $59.73.

12:00 EST Estee Lauder rises 13.8% - Estee Lauder is up 13.8%, or $18.45 to $152.56.

12:00 EST Sunnova Energy falls -9.6% - Sunnova Energy is down -9.6%, or -95c to $8.95.

11:58 EST 4D Molecular cystic fibrosis treatment granted FDA orphan designation - 4D Molecular Therapeutics' adeno-associated virus gene therapy comprised of a transgene cassette encoding codon-optimzed human CFTR delta R was granted FDA orphan designation as a treatment of cystic fibrosis, according to a post to the agency's website. Reference Link

11:46 EST DocuSign down 6% after report of cooling interest from PE suitors

11:26 EST Valneva sells Priority Review Voucher from FDA for $103M - Valneva announced earlier today that it sold the Priority Review Voucher it received from the Food and Drug Administration for $103M. The company was awarded a tropical disease PRV in November 2023 following FDA approval of Ixchiq, its single-dose, live-attenuated vaccine indicated for the prevention of disease caused by chikungunya virus. Valneva said will invest proceeds from the sale into its R&D projects, including the co-development of its Phase 3 vaccine candidate against Lyme disease, additional clinical trials for its chikungunya vaccine Ixchiq and the expansion of the company's clinical pipeline. Thomas Lingelbach, Chief Executive Officer of Valneva, said, "This non-dilutive capital provides an important source of additional funding to advance the continued development of our clinical pipeline. As shown with the recent approval of our chikungunya vaccine, we remain committed to growing our portfolio of vaccines addressing unmet medical needs which have the potential to transform people's lives."

11:02 EST FirstService raises quarterly dividend 11% to 25c per share - FirstService announced that its Board of Directors has approved an 11% increase in the quarterly cash dividend on the outstanding Common Shares of the Company over the previous 22.5c per Common Share and declared a quarterly dividend of 25c per Common Share. The dividend is payable on April 5, 2024 to holders of Common Shares of record at the close of business on March 29, 2024.

10:20 EST Morphosys Ag (ADR) trading resumes

10:15 EST Morphosys Ag (ADR) trading halted, volatility trading pause

10:00 EST Graham rises 11.7% - Graham is up 11.7%, or $2.31 to $22.09.

10:00 EST Ameresco falls -7.7% - Ameresco is down -7.7%, or -$1.64 to $19.46.

10:00 EST Air Products falls -14.7% - Air Products is down -14.7%, or -$37.84 to $220.32.

09:51 EST Estee Lauder sees returning to organic sales growth in mainland China in 2H - The company entered Q3 with momentum in brick and mortar in mainland China, Estee Lauder said on its Q2 earnings conference call.

09:47 EST Catalent rises 9.2% - Catalent is up 9.2%, or $5.01 to $59.52.

09:47 EST Estee Lauder rises 15.7% - Estee Lauder is up 15.7%, or $21.10 to $155.22.

09:47 EST JinkoSolar falls -8.1% - JinkoSolar is down -8.1%, or -$2.12 to $24.00.

09:45 EST Chenghe Acquisition Co trading resumes

09:39 EST Forward Air provides January LTL Expedited Freight operating statistics - Forward Air provided the following LTL Expedited Freight operating statistics for January 2024. During this period, weight per shipment increased 9.8%, pounds per day also increased 9.2% compared to the same period last year. Finally, revenue per ton mile increased 1.9% over the same period last year, excluding fuel. Tom Schmitt, Chairman and CEO of Forward, commented: "We continue to improve on the three metrics that matter most to us - increasing tonnage, refining freight quality and maximizing revenue per shipment. We have executed the first phase of the operational synergies ahead of schedule, folding Omni linehaul into the Forward Air network, which led to higher than 20 percent year over year pounds per day increase in the most recent week. We look forward to updating the market on a comprehensive plan and key milestones in the weeks ahead."

09:33 EST Verizon appoints Brian Higgins as chief customer experience officer - Verizon (VX) is investing more in customer experience with the creation of an organization dedicated solely to creating the best experiences for customers and employees. Under Verizon Consumer CEO Sowmyanarayan Sampath, Brian Higgins has been appointed as the company's first-ever Chief Customer Experience Officer for the consumer group. Former Walmart (WMT) executive Dory Butler will join Higgins as senior vice president of Customer Experience, where she will lead the development and delivery of high-quality sales and service experiences focusing on the end-to-end consumer journey. The company said, "The Customer Experience Organization will invest heavily in transforming the way customers do business with Verizon, and how our employees serve them. Focus areas include AI and personalization, digital channel and systems functionality and delivering best-in-class experiences across all consumer touch points. The team will create a more simplified approach and help deliver customized experiences based on customers' and employees' unique needs." Higgins previously served as senior vice president of Device Marketing and Consumer Product where he led all product and marketing for the Verizon Consumer Group.

09:30 EST Caterpillar says supply chain constraints have started to ease - Says supply chains better, but "still a ways to go." Expects China market to be "relatively weak" in FY24. Expects price increases to exceed manufacturing costs for the year.

09:29 EST Bowlero boosts share repurchase program to $200M - Bowlero said its board authorized a time extension and an increase to its share repurchase program, replenishing the authorized repurchase amount to $200M and removing the program expiration date. "The timing of the repurchases and the actual amount repurchased will depend on a variety of factors, including the market price of the Company's shares, general market and economic conditions, and other factors," the company said.

09:24 EST WNS Holdings announces client intent to terminate - WNS over the weekend disclosed in its Form 6-K filed with the SEC the following information in Part III Risk Factors: "For example, one of our top five customers by revenue contribution in fiscal 2024, which is in the HCLS SBU, served a termination notice on January 31, 2024. The customer accounted for 4.1%, 6.5% and 7.3% of our revenue and 4.3%, 6.8% and 7.9% of our revenue less repair payments in fiscal 2024, fiscal 2023 and fiscal 2022, respectively. This termination is effective July 1, 2024, and does not impact our revenue in fiscal 2024. We are in discussion with the customer around the support required for the transition of the services and are currently ascertaining the related financial and accounting impact."

09:24 EST VivoPower's Tembo EUV kit deliveries have commenced - Tembo E-LV, a subsidiary of the Nasdaq listed B Corp, VivoPower International PLC, announces that it has begun delivery of its next generation Electric Utility Vehicle, EUV, powertrain conversion kits. The first delivery of kit components were made to Access Industrial Mining, Tembo's exclusive distributor in Canada. Following completion of Access's successful testing program of the Tembo converted 4x4 Landcruiser in Europe in 2023, Access placed an initial order for EUV powertrain conversion kits. Further testing was then conducted across both hardware and software elements of the EUV powertrain conversion kits. This was pursuant to a definitive agreement for Access to purchase 1,675 Tembo EUV conversion kits over a period of five years. Kevin Chin, Chairman and CEO of VivoPower, said: "For Tembo, quality and safety are of paramount importance. Following a disciplined testing program over the last 12 months, we are very pleased to have begun delivery of the next generation EUV conversion kits and look forward to supporting our valued partner, Access as well as our other partners across the globe to electrify their utility vehicle fleets. In doing so, we look forward to helping them meet their commercial objectives, including in relation to sustainability goals."

09:21 EST Camber Energy announces additional purchase order for waste treatment system - Camber Energy announce that Planeteq, the exclusive distributor in the United Kingdom for Viking Ozone Technology's portfolio of patented waste treatment systems, issued a purchase order for a VKIN-6000/A Waste Treatment unit, which is designated for delivery to a hospital in the United Kingdom within the National Health Service Trus.

09:18 EST Comtech awarded $48M contract extension from Washington State - Comtech announced that Washington State recently awarded the company a $48M contract extension to continue providing Next Generation 911 services over the next five years, with the option to extend through 2034. Washington State initially contracted Comtech to design, deploy and operate next generation public safety technologies and secure and reliable communications capabilities in 2016.

09:15 EST Ainos submits clinical hold complete response on Phase II trial of VELDONA - Ainos has submitted the clinical hold complete response to the U.S. Food and Drug Administration for conducting a Phase II trial of its low-dose oral interferon-alpha formulation, VELDONA, for treatment of mild COVID-19 symptoms. If approved, the Company's Phase II trial is expected to involve a multicenter, parallel, randomized study conducted in Taiwan to evaluate the efficacy of VELDONA in subjects with mild COVID-19 symptoms during the third quarter of 2024. Ainos' recently-commenced VELDONA manufacturing process fully complies with both Pharmaceutical Inspection Co-operation Scheme Good Manufacturing Practice and the U.S. FDA's Current Good Manufacturing Practice regulations. The updated Chemistry, Manufacturing, and Controls information indicates that the stability of VELDONA can exceed the minimum shelf life of biologicals. Ainos intends to submit a number of additional IND applications during the second half of 2024, including Phase II/III studies for treatment of oral warts in HIV-seropositive patients, and Phase II/III studies for Sjogren's syndrome.

09:12 EST Varonis introduces Managed Data Detection and Response - Varonis Systems introduced Varonis Managed Data Detection and Response, the industry's first managed service dedicated to stopping threats at the data level. Unlike traditional MDR services that are endpoint- and network-centric, MDDR focuses on threats to data. The offering combines Varonis' award-winning threat detection technology and automation with a global team of elite threat hunters, forensics analysts, and incident responders who investigate and respond to threats 24x7x365.

09:11 EST Wrap Technologies reduces workforce by 30% - Wrap Technologies announces an initiative to position the company for growth in 2024 and beyond. The Company has reduced its labor force by 30%, representing $2.4M in annual savings, in the past 45 days through outsourcing and headcount reductions. To position for the future, the Company is expanding manufacturing capacity in its Tempe facility and building out a robust enterprise-level sales and marketing team. These measures should enable Wrap to meet the increasing global demand for its solutions while driving shareholder value. Wrap is implementing various cost-saving measures to optimize the corporate structure while investing in near and long-term revenue opportunities. These measures include digitization initiatives, headcount reductions and strategic outsourcing. These steps have enabled Wrap to achieve material cost savings while redirecting investment to higher ROI initiatives. Wrap intends to increase its production capacity through the expansion of its manufacturing operations in Tempe, Arizona to meet the growing global demand for the BolaWrap Remote Restraint device. The manufacturing facility will leverage state-of-the-art technology, that should result in improved throughput. Wrap is redirecting investment towards its sales and marketing infrastructure to capitalize on industry tailwinds. This investment should enable the expansion of Wrap's corporate headquarters in Miami, Florida and the continued recruitment of top-tier enterprise-level talent on its executive and corporate teams.

09:08 EST Safe and Green Development executes contract to sell St. Mary's site for $1.35M - Safe and Green Development announces that it has entered into an agreement to sell its St Mary's property to Pigmental Studios for $1.35 million. The St Mary's property consists of approximately 29 acres zoned for a manufacturing facility. After discussions with the City & Pigmental Studios, the Company decided to sell the property to accommodate Pigmental Studios' expansion in the area. The Company remains interested in the St Mary's region and will remain active via its investment in the Cumberland Inlet Project. David Villarreal, President & CEO of Safe and Green Development Corporation, stated, "It has been a pleasure to deal with Pigmental and I could not be happier that the St Mary's property is in the hands of such a great company. We believed this was the opportune time to sell the property which sale strengthens our balance sheet and provides us with the flexibility to move forward on other real estate properties and various projects that we are developing and considering."

09:07 EST Verizon deploys 130,000 new O-RAN capable radios in its network - Verizon has now deployed over 130,000 O-RAN capable radios which includes the massive MIMO radios as part of the previously announced 15,000 O-RAN compliant virtualized cell sites with O-RAN compliant baseband units in its commercial Radio Access Network. "Verizon is fully supportive of O-RAN technology and is focused on commercializing an operationally sound O-RAN architecture," said Adam Koeppe, SVP of Technology Planning at Verizon. "Our commitment to developing O-RAN standards and to deploying compliant equipment in our active Radio Access Network is helping to drive the industry forward which will result in a variety of tangible benefits for our customers who expect leading-edge technology from Verizon."

09:06 EST Riot Platforms produced 520 bitcoin in January - January bitcoin produced: 520; average bitcoin produced per day 16.8. Bitcoin held: 7,648. Bitcoin sold: 212. Deployed hash rate: 12.4 EH/s. Deployed miners: 112,944. Bitcoin sales - net proceeds: $9.5 million. "Riot had a strong month in January, mining 520 Bitcoin while utilizing our unique power strategy," said Jason Les, CEO of Riot. "Texas experienced extreme cold during the month, which led to increased demand for power. During periods of high demand, Riot's power curtailment efforts helped to stabilize the grid and generated $3.3 Million in Power and Demand Response Credits, equivalent to approximately 77 Bitcoin based on the average price of Bitcoin during the month. Riot's unique power strategy is central to positioning us as one of the lowest cost miners, and is a key competitive advantage, alongside our unmatched balance sheet strength and vertically integrated operations, as our industry transitions through the upcoming Bitcoin halving."

09:05 EST Intelligent Bio Solutions announces exercise of warrants from $1.77M in proceeds - Intelligent Bio Solutions announced an agreement between the Company and several current warrant holders to exercise certain existing Series E Warrants to purchase up to an aggregate of 606,064 shares of common stock that were issued on October 4, 2023, in an underwritten public offering. The Existing Warrants have an exercise price of $2.9232 per share. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to a registration statement that was filed and declared effective by the Securities and Exchange Commission. The gross proceeds to the Company from the exercise of the Existing Warrants are expected to be approximately $1.77 million prior to deducting placement agent fees and estimated offering expenses. In consideration for the immediate exercise of the Existing Warrants for cash, the exercising holders will receive new unregistered warrants to purchase shares of common stock in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended. The Replacement Warrants will be exercisable into an aggregate of up to 606,064 shares of common stock, at an exercise price of $4.50 per share, and a term of exercise equal to five-and-one-half years from issuance. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the warrant exercise transaction.

09:04 EST Yiviva signed MOU with AstraZeneca to establish research, development collab - Yiviva signed a memorandum of understanding, MOU, with AstraZeneca China to establish a research and development collaboration, collab, at AstraZeneca's Innovation Campus in Chengdu, China. The signing ceremony took place at the 2023 China International Import Expo at the National Exhibition and Convention Center in Shanghai. To address global unmet medical needs, Together Yiviva and AstraZeneca China will jointly build platforms for scientific research transformation and industrial development led by academicians and experts with the aim to modernize botanical medicines in accordance with new regulatory pathways for botanical medicines by the United States Food and Drug Administration and China National Medical Products Administration.

09:03 EST Galaxy Gaming appoints Michael Ratner as EVP, product - Galaxy Gaming announced the appointment of Michael Ratner as the company's new Executive Vice President of Product. Ratner developed significant skills in Product Management, focusing on games and casino management systems. His Product Management career includes experience with Atronic, Paltronics, Bally Technologies, Konami, and, most recently, IGT.

09:02 EST SEI Investments names Sean Denham as CFO, succeeding Dennis McGonigle - SEI announced the appointment of Sean Denham as an Executive Vice President and CFO, reporting to CEO Ryan Hicke. Denham's employment will begin on March 18, and his appointment as CFO will be effective on the day following the resignation of current CFO Dennis McGonigle, whose departure plans were announced by SEI in July 2023. SEI currently expects McGonigle's resignation to be effective on the day of the filing of the company's first-quarter 2024 Form 10-Q. Denham succeeds McGonigle, who has served in a number of different roles and leadership positions at SEI for nearly 40 years. Upon his appointment, Denham will be responsible for leading finance and accounting, corporate controllership, business management, enterprise risk management, and investor relations functions, as well as administering the internal audit function.

09:00 EST Wrap Technologies trading halted, news pending

08:55 EST Mangoceuticals accepting preorders for PRIME - Mangoceuticals announced that it is offering 2 months of free 'PRIME' by MangoRx, Powered by Kyzatrexmfor the first 1,000 male subscribers who express interest in subscribing to the oral testosterone replacement protocol. Interested subscribers will also be prompted to preorder a minimally invasive FDA approved at-home blood collection test kit through their nationwide lab partnership with Trybe Labs, which is being offered to MangoRx subscribers at preferred discounted prices. PRIME will be available to MangoRx customers at a price of $199/month with eligibility to receive an additional 10% discount per month if subscribed to another MangoRx product

08:52 EST PodcastOne renews agreement with Kelly Stafford's 'The Morning After' - PodcastOne entered into a new agreement with Kelly Stafford for her The Morning After with Kelly Stafford & Hank Podcast for the exclusive distribution and advertising sales rights of the podcast. The headline-making Apple charting show launched in 2021 and joined the PodcastOne network in 2022.

08:46 EST Omniq acquires CodeBlocks for $1.275M - OMNIQ Corp announced that its wholly owned subsidiary acquired CodeBlocks, a Fintech software company with over 80,000 deployments. OmniQ, acquired CodeBlocks in exchange for NIS 4,666,664. The consideration is payable in seven equal installments with the final payment due on January 11, 2025. The purchase Agreement closed on February 1, 2024.

08:41 EST Ispire Technology opens ISO- and GMP-certified Malaysia manufacturing facility - Ispire Technology announced the opening of its new ISO- and GMP-certified 31,000 sq. ft. manufacturing facility in Malaysia, which is poised to help expedite market entry for businesses seeking to enhance their cannabis and nicotine product lines.

08:39 EST PureCycle Technologies reaches agreement in principle to buy Ironton bonds - PureCycle Technologies announced that PureCycle: Ohio has reached an agreement in principle with holders of a majority of the Southern Ohio Port Authority Exempt Facility Revenue Bonds, Tax-Exempt Series 2020A, of which $219,550,000 principal amount is outstanding, to purchase for cash, at a purchase price equal to $1,030 per $1,000 principal amount of Bonds purchased. In addition to the Majority Holders, additional holders of the Series 2020A Bonds may participate in the Purchase. Holders of the Series 2020A Bonds that participate in the Purchase will be required to consent to certain proposed amendments to the bond documents governing the Series 2020A Bonds and closing of the Purchase will require that no less than Majority Holders participate in the Purchase and provide their Consents. The Proposed Amendments will eliminate certain restrictive covenants and events of default contained in the bond documents governing the Series 2020A Bonds that are permitted to be eliminated with the consent of the Majority Holders. The Consents will become effective upon closing of the Purchase. In addition to the Purchase of the Series 2020A Bonds, PCO may purchase Southern Ohio Port Authority Subordinate Exempt Facility Revenue Bonds, Tax-Exempt Series 2020B, of which $20,000,000 principal amount is outstanding, and Southern Ohio Port Authority Subordinate Exempt Facility Revenue Bonds, Taxable Series 2020C of which $10,000,000 principal amount is outstanding for which Consents shall also be required to the extent such Bonds are purchased. The Purchase Price is calculated in part to compensate the Sellers for default interest accruing from January 2, 2023 through December 31, 2023, and any other accrued and unpaid interest on the Bonds from, and including, the most recent interest payment date up to the closing date of the Purchase. The Purchase Price does not include any default or penalty interest accruing from January 1, 2024, that may otherwise be owed and Holders that participate in the Purchase will waive their respective right to such default or penalty interest. The Proposed Amendments to the Indenture of Trust, dated as of October 1, 2020, between Southern Ohio Port Authority and UMB Bank, N.A., as trustee and the Loan Agreement by and between the Issuer and PCO, dated as of October 1, 2020 are expected to include, but are not limited to, the following: Elimination of certain restrictive covenants and events of default contained in the Indenture and the Loan Agreement and other transaction documents that are permitted to be eliminated with the consent of the Majority Holders; and Release of funds on deposit in accounts in the Trust Estate in an amount proportionate to the percentage of the aggregate principal amount of the Bonds that Sellers submit for Purchase, which released funds will be used by PCO to effectuate the Purchase. The Purchase is intended to allow the Company to provide additional flexibility in completing commissioning activities at the Ironton Facility. The Company expects to fund the Purchase with those Trust Estate funds released under the Proposed Amendments together with available cash on hand. The Purchase will not occur unless the Majority Holders participate in the Purchase and provide Consents to the Proposed Amendments. The Purchase is expected to close no later than February 15, 2024.

08:37 EST ICE reports January total ADV up 30% y/y, open interest up 20% y/y - Intercontinental Exchange reported January 2024 trading volume and related revenue statistics: Total average daily volume or ADV, up 30% y/y, including record options of 1.6M lots; open interest or OI, up 20% y/y, including record OI of 87.3M lots on January 25 Record Energy ADV up 33% y/y; OI up 22% y/y, including record OI of 56.3M lots on January 25;Total Oil ADV up 31% y/y; OI up 25% y/y. Brent ADV up 14% y/y; OI up 6% y/y and WTI ADV up 59% y/y; OI up 50% y/y...North American gas ADV up 38% y/y; OI up 21% y/y...

08:35 EST Nocturne Acquisition announces postponement of EGM - Nocturne Acquisition announced that the Board of Directors has voted in favor of a second postponement of the meeting date for the Extraordinary General Meeting that was to be held on January 30, 2024 for shareholders to vote on the proposed business combination with Cognos Therapeutics, Inc. The Extraordinary General Meeting that was postponed until February 6, 2024 has been postponed further and will now be held virtually on February 27, 2024 at 9:00 a.m. Eastern Time. The Company plans to continue to solicit proxies from shareholders during the period prior to the Extraordinary General Meeting. The record date for the Extraordinary General Meeting remains the close of business on December 29, 2023. No changes have been made in the proposals to be voted on by the shareholders at the postponed meeting. Shareholders who have previously submitted their proxy or otherwise voted and who do not want to change their vote need not take any action. Stockholders as of the record date may vote, even if they have subsequently sold their shares. The deadline by which shareholders must exercise their redemption rights in connection with the Extraordinary General Meeting has been extended to two business days prior to the second postponed meeting.

08:34 EST Treasure Global CEO Sam Teo purchases 1.17M shares - Treasure Global announced that CEO of the Company, Sam Teo, increased his stake in the Company by purchasing 1,170,000 shares in the open market, totaling an investment of USD $98,397 with each share acquired at $ 0.0841 per share. Following this transaction, Mr. Teo now holds an aggregate of 5.11% of the issued and outstanding voting shares.

08:32 EST Foresight Autonomous completes project with Japanese vehicle manufacturer - Foresight Autonomous Holdings announced the successful completion of two proof of concept, POC, projects with a leading Japanese vehicle manufacturer, the initiation of these projects was reported by the Company on August 14, 2023. The vehicle manufacturer, currently employing stereo cameras in its advanced driver assistance systems, ADAS, evaluated the accuracy of Foresight's unique automatic calibration capabilities to enhance 3D depth perception. Following satisfactory results, the parties are exploring co-development initiatives for further evaluation of the solution's capabilities. Prospective collaboration may involve integrating Foresight's technology into the passenger vehicles of the manufacturer. This integration has the potential to enhance precision in distance measurement, as well as improve object detection and classification, thereby elevating the overall safety system of the automaker's vehicles.

08:28 EST China Liberal Education regains compliance with Nasdaq listing requirement - China Liberal Education received a written notification from the Nasdaq Listing Qualifications Department on February 2, informing the company that it has regained compliance with the Nasdaq's minimum bid price requirement and the matter is closed. The notification letter received from Nasdaq noted that the company evidenced a closing bid price of its ordinary shares at or greater than the $1.00 per share minimum requirement for the last 10 consecutive business days, from January 19 to February 1.

08:27 EST CBRE Group to acquire J&J Worldwide Services for $800M in cash - CBRE Group announced a definitive agreement to acquire J&J Worldwide Services from Arlington Capital Partners. The initial purchase price is $800M in cash, plus a potential earn-out of up to $250M, payable in 2027, subject to the acquired business meeting certain performance thresholds. In 2024, J&J is projected to produce more than $525M of revenue and approximately $65M of EBITDA, continuing its recent track record of low double-digit annual growth. Additionally, CBRE expects to benefit from tax attributes and synergies arising from the transaction. The acquisition is expected to be accretive to CBRE's earnings in 2024. J&J primarily serves the U.S. Department of Defense through long-term, fixed-price contracts. The company employs more than 3,300 people worldwide, serving more than 250 hospitals, clinics and military installations primarily in the United States as well as in Europe, Asia, the Caribbean, and the Middle East.

08:26 EST Sapiens, Binah.ai partner to improve risk management - Sapiens and Binah.ai, a health and wellness check software provider, announced a partnership to empower more insurance companies worldwide to use client-provided health data for improved risk management and value-added services at reduced costs. The partnership enables Binah.ai to leverage Sapiens' strong global presence and provide Sapiens' customers with seamless access to Binah.ai's software-based health and wellness check technology.

08:25 EST Uncle Bud's to launch new premium health, wellness products - Pressure BioSciences is hosting a teleconference Monday, February 5th, 4:30PM EST to discuss the recent acquisition of natural health and wellness innovator Uncle Bud's, as well as other on-going opportunities. Uncle Bud's Health and Wellness is announcing the planned launch of its UltraShear-processed "Premium Collection" of nanoemulsified products. The collection, highlighted by its flagship product - the CBD Body Revive Spray with 1200mg of Nano CBD - will be processed with PBIO's multi-patented UltraShear Technology, and is expected to redefine the standards of effectiveness and quality in CBD and other products. These products represent the pinnacle of innovation, quality, and commitment to natural, clean wellness solutions. The Premium Collection launch is expected on or before March 1, 2024. Embodying Uncle Bud's commitment to safety and environmental responsibility, all UltraShear Premium Collection products will be crafted from 100% natural, clean ingredients, and GMO-free. For the launch of the new premium products, Uncle Bud's is inaugurating a new website category dedicated exclusively to the innovation and quality of the Premium Collection product line. The launch of the initial product - CBD Body Revive Spray with 1200 mg of Nano CBD for powerful, fast-acting relief in a convenient spray form - offers an essential addition in any wellness regimen and marks the beginning of a series of groundbreaking premium products designed to meet the needs of consumers looking for the highest quality and performance in natural and effective wellness solutions.

08:22 EST IntelGenx announces results from POC study of VetaFilm platform - IntelGenx announced positive results from a proof-of-concept, POC, study to assess the palatability, owner-perceived acceptability, and ease of repeated administration of IntelGenx's VetaFilm platform in healthy dogs and cats. The POC study was conducted through a research collaboration with the University Prince Edward Island, one of North America's leading veterinary universities. Key findings included: The VetaFilm FDOFs were well accepted and well tolerated by both dogs and cats; Repeated dosing showed high continued acceptance rates in both species with little or no effect of time on the continued acceptance of the VetaFilm FDOFs; Overall, 100% of dog owners and 67% of cat owners felt that administration of the VetaFilm FDOFs was "very easy" or "easy"; and 95% of dog owners and 82% of cat owners identified VetaFilm FDOFs as the preferred method of medication administration.

08:21 EST Maris-Tech receives order for approximately $190,000 from return customer - Maris-Tech announced that it has received an order for approximately $190,000 from a return customer in the defense industry, for a video recording, streaming and debriefing solution designed for gun sight in tactical applications. "This order for a product to use with gun sights based on Maris-Tech's intelligent video transmission and miniaturization technologies highlights the unique design and exceptional capabilities of our integrated solutions to support a wide range of tactical and other applications and to meet the demanding requirements of the defense industry," said Israel Bar, CEO of Maris-Tech.

08:20 EST Celldex announces upcoming presentation of barzolvolimab Phase 2 results - Celldex Therapeutics announced that an abstract describing 12 week results from the Company's Phase 2 clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria refractory to antihistamines, including patients with biologic-refractory disease, has been accepted as a late breaking oral presentation at the American Academy of Allergy, Asthma & Immunology, AAAI, Annual Meeting 2024 being held in Washington, DC on February 23-26, 2024. Abstracts will be available on the meeting website today, February 5, 2024. The abstract is comprised of the topline 12-week primary endpoint results the Company disclosed on November 6, 2023.

08:20 EST Sprinklr announces Chief Revenue Officer Ohls to leave effective March 16 - Today, Sprinklr also announced that Chief Revenue Officer (CRO) Paul Ohls has made the decision to leave Sprinklr effective March 16.. He will support Mr. Harvey until his departure to ensure a seamless transition. "Paul has had an immeasurable impact on Sprinklr's success over more than five years in sales leadership, most recently as CRO. He inspired a passion for how our platform provides value to our customers and helped build a foundation for our next phase of growth and scale. His contributions and friendship are greatly valued, and we wish him well," continued Thomas. Sprinklr also reaffirms its financial guidance for the fourth quarter of fiscal 2024 and the full year fiscal 2024, as provided in a press release issued on December 6, 2023.

08:19 EST Caterpillar raises FY24 ME&T free cash flow target to $5B-$10B from $4B-$8B - Expects to return substantially all ME&T free cash flow to shareholders over time. Says strong balance sheet and liquidity.

08:17 EST American Pacific regains 100% interest in Madison copper-gold mine project - American Pacific Mining announces that Kennecott Exploration Company, a subsidiary of the Rio Tinto Group in collaboration with American Pacific, has agreed to discontinue the 11-year Madison earn-in agreement to acquire a 70% interest in American Pacific's Madison Mine Project. American Pacific would like to thank the regional Kennecott team for its collaborative approach at Madison over the years. The Company is pleased to regain 100% ownership and control of Madison, which now becomes the Company's lead solely owned property. The Madison Project was host to small-scale production, which concluded in 2012 with 2.7 million pounds of copper produced at grades ranging from 20-35% copper. Subsequent drilling at Madison in 2017 included 30.18 metres of 24.50 grams per tonne gold and 0.39% Cu and 10.97 m of 41.65 g/t Au and 0.38% Cu. Drilling in 2017 also included a drill hole completed to 377 m depth, which intersected altered latite porphyry material at 301 m and has yet to be followed up on. The final drill hole from the last drill campaign completed by Rio intersected 6.53 m of 14.44 g/t Au and 0.11% Cu in an area that remains open approximately 100 m down plunge from the known skarn mineralization. The Company intends to proceed with the 2024 drill program as planned in collaboration with Kennecott. The program has been designed to include drill holes within the skarn that will aim to confirm and extend mineralization encountered in historical drilling.

08:15 EST Candel Therapeutics provides update on upcoming milestones - Candel Therapeutics highlighted recent successes across the Company's immunotherapy portfolio and provided updates on multiple upcoming milestones. 2024 Anticipated Data Readouts and Key Catalysts: Candel plans to announce 6 anticipated readouts across its 3 platforms in 2024, which include novel clinical and biomarker data in lung cancer, pancreatic cancer, brain cancer and a potentially registrational phase 3 clinical trial in prostate cancer. Phase 2 topline overall survival data for CAN-2409 in NSCLC expected in Q2 2024; Phase 2 updated overall survival data for CAN-2409 in borderline resectable pancreatic cancer expected in Q2 2024; New preclinical data on the second drug candidate from the enLIGHTEN(TM) Discovery Platform expected by Q3 2024; Phase 1 data for CAN-3110 in recurrent high-grade glioma expected in 2H 2024 for the multiple injection cohort; Phase 2 topline data for CAN-2409 in low-to-intermediate-risk, localized, non-metastatic prostate cancer expected in Q4 2024; Phase 3 topline data for CAN-2409 in localized intermediate/high-risk prostate cancer expected in Q4 2024.

08:13 EST Inspired Entertainment announces Nasdaq acceptance of plan of compliance - Inspired Entertainment announced that it has received notification from the Nasdaq Stock Market stating that Nasdaq has accepted the Company's plan of compliance to file a Form 10-Q for the quarter ended September 30, 2023 by no later than February 28, 2024. In addition to working to file the September 30, 2023 Form 10-Q on or before February 28, 2024, the Company is working diligently to complete the 10-K/A for the year ended December 31, 2022 with restated financial statements, as well as Forms 10-Q/A for the quarters ended March 31, 2023 and June 30, 2023, and aims to file such reports as soon as practicable, on or before February 28, 2024.

08:12 EST Warrantee regains compliance with Nasdaq filing requirements - Warrantee announced that it had received a letter from the Nasdaq Office of General Office dated February 1, 2024, confirming that the Company had regained compliance with Nasdaq's filing requirement set forth in Listing Rule 5250(c)(1), since the Company filed its Form 20-F for the period ended March 31, 2023 on January 31, 2024. As a result, the scheduled hearing before the Hearings Panel on February 8, 2024 relating to the delisting determination resulting from the failure to file such Form 20-F had been cancelled and the matter was closed. The Company's American Depositary Shares will continue to be listed and traded on the Nasdaq Capital Market under the symbol "WRNT."

08:11 EST Inspire Medical announces Chair Nelson to retire, CEO Herbert named Chair - Inspire Medical Systems announced the retirement of Marilyn Carlson Nelson as Chair of its Board of Directors and the appointment of Chief Executive Officer Timothy Herbert to the additional role of Board Chair, to be effective at the conclusion of the Company's Annual Meeting of Stockholders scheduled to occur on May 2, 2024. Herbert is the founder of Inspire and has served as President and CEO since May of 2007.

08:10 EST American Oncology Network welcomes Bay Hematology Oncology to network - American Oncology Network welcomes Bay Hematology Oncology to its expanding network of practices. Bay Hematology Oncology includes a team of accomplished Board-certified physicians David Smith, MD; Muhammad Siddique, MD; and Pamela Simpson, MD; and a dedicated care staff of four advanced practitioners who are experienced in treating an array of blood disorders and cancer-related diseases. The practice currently has two clinic locations: one in Easton and the other in Centreville. In addition to the current patient services offered, as part of the AON partnership, Bay Hematology Oncology's two clinics will offer additional patient resources. Such resources include in-house pathology services, enhanced in-house specialty pharmacy for oral oncolytic medication and care coordination for patients among other benefits. Patients can continue to expect the same high level of care provided by the physicians and care team.

08:09 EST VS Media partners with The Pinkfong Company, Kind Parrot Group - VS Media Holdings partnered with global entertainment company The Pinkfong Company and fine dining provider King Parrot Group to launch a VS Lounge in Hong Kong's Central Waterfront. VS Lounge is an all-day family-oriented event, featuring Pinkfong's Baby Shark-themed interactive games, a delectable dining experience during the day and an 'Open Mic' and live music performance in the evening. The event series will run from February 2 through February 25, 2024, at the Central Waterfront, spanning across the Lunar New Year and Valentine's Day with a unique celebratory experience. "We are thrilled to bring the beloved global kids icon Baby Shark to Central Hong Kong. VS Lounge demonstrates our ability in connecting top tier content creators with customers in both online and offline settings," said VS Media Founder & CEO Ivy Wong. "We look forward to welcoming families to immerse themselves in a series of fun and interactive activities at VS Lounge, extending the joyous celebrations from Lunar New Year to Valentine's Day and beyond and injecting positive energy into the local community."

08:08 EST Ocuphire Pharma announces presentation on APX3330 - Ocuphire Pharma announced that clinical data from its ZETA-1 trial on a person-level scale evaluating APX3330 in diabetic retinopathy were presented at the 21st Annual Angiogenesis, Exudation, and Degeneration 2024 Conference, which took place virtually on Saturday, February 3, 2024. The presentation was titled APX3330 Oral Treatment to Slow the Progression of Diabetic Retinopathy Using a Binocular DRSS Severity Scale as a Registrational Endpoint. Presentation Highlights: ZETA-1 was a Phase 2 trial of oral APX3330 in DR. It was a multi-center, randomized, double-masked, placebo-controlled trial that enrolled 103 subjects. Topline results were announced by Ocuphire in January 2023. In November, a successful end-of-phase 2 meeting outcome was announced with an agreement on Phase 3 primary endpoint of 3-step worsening on a binocular 17-step person-level scale using the Diabetic Retinopathy Severity Scale. Analysis of ZETA-1 Phase 2 results using the person-level scale, showed only 5% of subjects treated with APX3330 had a clinically meaningful greater than or equal to 3-step worsening in DRSS at Week 24 on this binocular person-level scale, compared with 13% of placebo patients. APX3330 showed favorable safety and tolerability in diabetic patients that continued dosing their medications through the study durations to manage their diabetic comorbidities.

08:08 EST Bowman Consulting acquires Vermont-based Trudell in accretive deal, no terms - Bowman Consulting Group announced the acquisition of Trudell Consulting Engineers and its wholly owned Vermont Underground Locators subsidiary or TCE, an engineering firm located just outside Burlington in Williston, Vermont....the firm provides civil engineering, landscape architecture, land surveying, utility locating and environmental services to clients throughout Vermont. "TCE is a dynamic engineering firm in a growing market with an extremely talented collection of professionals," said Gary Bowman, chairman and CEO of Bowman... Financed with a combination of cash, seller notes and equity, the acquisition falls within previously discussed target multiples and operating metric ranges and is expected to be immediately accretive. The Company anticipates the acquisition will initially operate at an annualized net service billing run rate of approximately $4.5 million. More detailed information on M&A activities, pipeline and guidance updates are provided in connection with scheduled quarterly and annual communications.

08:07 EST Global-e Online appoints CEO Europe, CTO and Chief Innovation Officer - Global-e Online appointed Cristian van Tienhoven as CEO Europe, promoted of Yehiam Shinder to the role of CTO and the transition of Eden Zaharoni, former CTO, to his new role as Chief Innovation Officer. van Tienhoven is set to lead Global-e's European team, having previously served as the COO of eBay UK, where he was responsible for their delivery and logistics solutions. Prior to that, he worked at Amazon for 8 years in the UK and the USA in various executive roles in the Marketplace, Payments and Physical Retail business units. Shinder will be promoted to the role of Chief Technology Officer, after stints as both Global-e's SVP Engineering and VP R&D. Before joining Global-e, he served as the Chief Information Officer at Kaltura, a publicly traded SaaS Video and OTT product company. Zaharoni is a 10+ year veteran of Global-e and current CTO. In her new capacity, Eden will lead a team dedicated to exploring and implementing new breakthrough technologies, particularly in the field of generative AI, to foster innovation across the company's business and operations.

08:06 EST VCI Global announces new material contract with Reveillon Group - VCI Global Limited announces its engagement by Reveillon Group Sdn Bhd, a Malaysian company operating in the food and beverage as well as the entertainment industry, as its initial public offering consultant. The projected revenue from this consulting service is expected to fall within the USD $4 million to USD $8 million range, subject to the valuation of the IPO. The anticipated IPO for Reveillon Group, aiming to list on Nasdaq, is expected to be completed in 2024/2025. "We are pleased to be selected by Reveillon and look forward to working with the team to provide them with the experience and resources to help them grow and mature. We are eager to share our experiences with Reveillon Group, contributing to the success of their upcoming IPO exercise and further solidifying our position as a trusted IPO consultant," said Dato' Victor Hoo, Group Executive Chairman and Chief Executive Officer of VCI Global.

08:04 EST SaverOne 2014 secures new customer, Egged Tours - SaverOne 2014 announced that it has secured a new customer, Egged Tours, with a significant contract to install 300 SaverOne Systems on all of its buses. In the coming month, 80 systems will be installed on Egged's buses, and following that, a further 220 systems are expected to be installed. Egged Tours operates the largest tour bus fleet in Israel.

08:04 EST Vanda Pharmaceuticals announces FDA update for supplemental NDA for Hetlioz - Vanda Pharmaceuticals received a notification from the FDA stating that as part of its ongoing review of Vanda's supplemental New Drug Application - sNDA - for Hetlioz in the treatment of insomnia characterized by difficulties with sleep initiation, the FDA has identified deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time. No deficiencies were disclosed by the FDA in the notification, and the FDA stated that the notification does not reflect a final decision on the information under review. The FDA had assigned a Prescription Drug User Fee Act target date of March 4 for the completion of its review of the sNDA. Vanda believes that the timing of the FDA's communication is part of an ongoing violation of the Federal Food Drug, and Cosmetic Act, or FDCA, which requires the FDA to either approve a new drug application or provide an opportunity for a hearing within 180 days after the filing of an application. Because Vanda submitted the sNDA on May 4, 2023, the FDA's deadline under the FDCA was October 31. 2023. The FDA has not complied with the statute and has not timely approved the application or provided an opportunity for a hearing within the statutorily prescribed timeframe. Vanda is also challenging the FDA's approvals of several generic versions of Hetlioz, which have been marketed since 2023.

07:58 EST Global Crossing Airlines CEO Edward Wegel to resign - Global Crossing Airlines Group announces the appointment of Chris Jamroz as Executive Chairman and Ryan Goepel as President. Mr. Goepel will continue to serve as CFO. The Board of Directors and Edward Wegel, the Company's CEO, have agreed that Mr.Wegel will resign his duties, rights, and obligations as an officer and Chairman and CEO of the Company, effective immediately. While the Company continues its search for a successor, the leadership team will report to the Executive Chairman of the Board. Ed Wegel will continue to serve on GlobalX's Board of Directors and as a GlobalX Senior Advisor.

07:53 EST Avicanna enters supply, licensing agreement with pharmaceutical company - Avicanna announces an exclusive supply agreement for two of the Company's proprietary topical products with a multinational pharmaceutical company. Pharma manufactures and markets a wide range of pharmaceuticals across 4 continents and has established commercial infrastructure in the European region that will be utilized for the initial launch of the selected products. Pharma has committed to launch the initial products in 6 European countries during 2024 with expectations of expanding throughout the region shortly after. Avicanna will be earning licensing fees associated to specific milestones and the parties have also agreed to specific minimum order quantities and efforts for Pharma to maintain the exclusivity. The exclusive supply agreement is for the Company's proprietary topical products that have been commercialized in the Canadian market under the RHO Phyto brand across several medical cannabis platforms including MyMedi.ca. Products Selected: The Ultra-CBD cream is a 3% CBD localized cream developed to target dermatology conditions. The cream is enrolled in previously announced observational real world evidence clinical trial with the Hospital for Sick Children related to Epidermolysis Bullosa. The CBG Transdermal Gel is a 2% CBD and 0.5% CBG gel developed to target local inflammatory and pain conditions. The gel is enrolled in previously announced observational real world evidence clinical trial on musculoskeletal pain and inflammation. The products have completed dossiers and will be registered and commercialized under applicable cosmetics legislation providing a route to market with the expected launch during the first half of 2024. The products will be manufactured using the Company's Colombian operations while utilizing Avicanna's own source of cannabinoids from majority owned subsidiary, Santa Marta Golden Hemp S.A.S. Additionally, the two companies have entered into a separate right of first refusal agreement related to the Company's SEDDS technology capsules for the same region.

07:40 EST PetroChina intends to deregister with U.S. SEC, terminate reporting obligations - PetroChina Company announced that the Company intends to deregister with the United States Securities and Exchange Commission and terminate its reporting obligations under the U.S. Securities Exchange Act of 1934, as amended. The Company filed a Form 25 with the SEC on August 29, 2022 to delist its American depositary shares from the New York Stock Exchange. The delisting became effective on September 8, 2022.The Company has terminated its ADS program on October 19, 2022. In light of the delisting of the ADSs and the termination of the ADS program, the Company intends to file a Form 15F with the SEC on Feb 5, 2024 to deregister the ADSs and the underlying H shares of the Company, and terminate its reporting obligations under section 13(a) and section 15(d) of the Exchange Act pursuant to Rule 12h-6 under the Exchange Act. Thereafter, all of the Company's reporting obligations under the Exchange Act will be suspended unless the Form 15F is withdrawn or denied. Deregistration and termination of the Company's reporting obligations under the Exchange Act are expected to become effective 90 days after its filing of Form 15F. Once the Form 15F is filed, the Company will publish the information required under Rule 12g3-2(b) of the Exchange Act on its website, http://www.petrochina.com.cn. The Company will continue to comply with its information disclosure and other obligations as a listed company under the relevant rules of The Stock Exchange of Hong Kong Limited and the Shanghai Stock Exchange as well as other applicable laws and regulations.

07:38 EST Post Holdings commences senior secured notes offering - Post Holdings intends to commence a private offering to eligible purchasers, subject to market and other conditions, of $875.0 million in aggregate principal amount of senior secured notes due 2032. The Notes will be secured obligations of the Company and will be guaranteed on a senior secured basis by each of the Company's existing and subsequently acquired or organized wholly-owned domestic subsidiaries that guarantee the Company's credit agreement or certain of its other indebtedness; however, immaterial subsidiaries, receivables finance subsidiaries and subsidiaries the Company designates as unrestricted subsidiaries will not be required to guarantee the Notes. The Company intends to use the net proceeds from the Notes offering, together with cash on hand, for purposes of repaying in full its outstanding $400.0 million incremental term loan under its credit agreement, which the Company borrowed in April 2023, redeeming its existing 5.75% senior notes due 2027 and paying the premiums, costs, fees and expenses associated with the offering, the term loan repayment and the notes redemption. To the extent there are any remaining net proceeds, the Company intends to use such proceeds for general corporate purposes, which could include, among other things, retirement or repayment of existing debt, acquisitions, share repurchases, capital expenditures and working capital. The final terms and amounts of the Notes are subject to market and other conditions and may be materially different than expectations. The offering is not conditioned upon the consummation of the redemption of the Company's 5.75% senior notes due 2027, which is expected to occur on March 1, 2024.

07:37 EST Palatin announced database lock for Phase 3 trial of dry eye disease candidate - Palatin Technologies announced database lock for its PL9643 MELODY-1 pivotal Phase 3 clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease, or DED. MELODY-1 has two co-primary efficacy endpoints: one clinical sign of DED and one clinical symptom of DED. If one or both co-primary end points are met, the study will be deemed a success and the secondary end points will be evaluated using a hierarchical testing strategy. The trial evaluated the safety and efficacy of the melanocortin agonist, PL9643 ophthalmic solution, compared to vehicle in patients with moderate-to-severe DED, for multiple sign and symptom endpoints, after treatment for 12 weeks. The remainder of the Phase 3 program, which includes the Phase 3 safety and efficacy study MELODY-2 and the open label MELODY-3 study are anticipated to commence patient enrollment in the second half of calendar year 2024.

07:36 EST Genprex: First person dosed in Phase 2a expansion of Acclaim-1 trial - Genprex (GNPX) announced that in January, the first patient was enrolled and dosed in the Phase 2a expansion portion of the company's Acclaim-1 clinical study of Reqorsa Therapy in combination with AstraZeneca's (AZN) Tagrisso to treat patients with late-stage non-small cell lung cancer. The company expects to complete enrollment of the Phase 2a expansion study by the end of 2024.

07:34 EST Verrica Pharmaceuticals files lawsuit against Dormer Laboratories - Verrica Pharmaceuticals announced that it has filed a lawsuit in the Eastern District of Pennsylvania against Dormer Laboratories, a Canada corporation requesting, among other relief, that the court enjoin Dormer Labs from marketing, selling, and distributing drugs containing cantharidin in the United States, as well as compensatory, statutory and punitive damages for Dormer Labs' violations of the federal Lanham Act and Pennsylvania law. The lawsuit arises out of Dormer Labs' false and misleading advertising and promotion of unapproved cantharidin-containing drugs to health care providers and other customers in the United States.

07:31 EST Microbot Medical submits an IDE application with U.S. FDA - Microbot Medical announced that it has filed an Investigational Device Exemption, IDE, application with the US Food and Drug Administration, FDA. The IDE application follows the completion of multiple preclinical activities performed to provide preliminary safety and effectiveness information, and its approval by the FDA would allow the company to commence its pivotal human clinical trial in the United States. "This is an important milestone for the company, and it is another step forward in our journey to achieve FDA clearance for the LIBERTY Endovascular Robotic Surgical System," said Harel Gadot, CEO, President and Chairman of Microbot Medical.

07:20 EST Optex Systems secures $2.8M award for Laser Protected Periscopes, Vision Blocks - Optex Systems Holdings has been awarded a new five year Indefinite Delivery Indefinite Quantity contract from the United States Defense Logistics Agency Land and Maritime for Sighting Systems. The maximum value for the five year IDIQ is estimated at $2.8 Million. The Laser Protected Periscopes and Vision Blocks are critical in mission capability for armored vehicles fielded by the U.S. Military.

07:17 EST Information Services EVP, registery operations Ken Budzak to retire - ISC also announces the upcoming retirement of Ken Budzak, Executive Vice President, Registry Operations, effective May 2024. During this transition period, the Company will undertake a process to fill the role, ensuring it aligns with our strategic objectives, while the strong team Ken has built will continue to provide the exceptional performance and service that our customers are accustomed to.

07:14 EST Helius Medical expands presence at 2025 APTA CSM - Helius Medical Technologies is expanding its presence at the 2024 American Physical Therapy Association, APTA, Combined Sections Meeting, CSM, held February 15 through February 17 at the Boston Convention and Exposition Center: In addition to exhibiting its innovative Portable Neuromodulation Stimulator at booth 7074, the company also is hosting an after-hours event on February 16. "Physical therapists are integral to the success of PoNS Therapy. PoNS Therapy requires them to use their clinical expertise to develop an appropriate treatment regimen that addresses the patient's specific deficits with a goal of improving their gait," said Whitney Patrickson, DPT, Helius' Director of Physical Therapy. "We're eager to engage with CSM attendees to discuss the therapeutic benefit as well as the flexibility and latitude that PoNS offers in tailoring the therapy to the needs of each patient."

07:13 EST Orchard Therapeutics announces first patient randomized in trial of OTL-203 - Orchard Therapeutics (ORTX), recently acquired by Kyowa Kirin (KYKOF) with the goal of accelerating the delivery of new gene therapies to patients around the globe, announced the first patient has been randomized at the M Health Fairview Masonic Children's Hospital in a registrational trial evaluating the efficacy and safety of OTL-203, an investigational hematopoietic stem cell gene therapy, in patients with the Hurler subtype of mucopolysaccharidosis type I, MPS-IH. The trial, referred to as HURCULES, compares treatment with OTL-203 to standard of care with allogeneic hematopoietic stem cell transplant, and is expected to enroll 40 MPS-IH patients at sites across the U.S. and Europe. "This is a substantial milestone in the development of OTL-203 as we work toward bringing an important new treatment option to children with MPS-IH and their families," said Leslie Meltzer, Ph.D., chief medical officer of Orchard Therapeutics. "Previously reported results from an earlier proof-of-concept study in patients showed robust metabolic correction, continued cognitive, motor, and physical development, as well as early improvements in skeletal, ocular and auditory health demonstrating that one-time treatment with OTL-203 has the potential to positively impact a broad range of clinical manifestations not fully addressed by the current standard of care."

07:12 EST Dorman Products releases fifth edition of award-winning OE Fix Guide - Dorman Products is announcing the release of OE FIX Guide Vol. 5, its award-winning publication highlighting its most innovative automotive repair solutions designed to help mechanics make faster, longer-lasting repairs. "We have heard from auto service centers around North America who read and enjoyed the OE FIX Guide and have been looking forward to this latest edition," said Steve Gisondi, Dorman's VP of Marketing. "This latest volume further incorporates the feedback we've heard by continuing to describe in detail our most helpful repair solutions as well as tell the stories behind our brand that wrenches have trusted for more than a century."

07:10 EST Volcon appoints John Kim as CEO - Volcon announces that John Kim has been appointed CEO. Kim has served on Volcon's Board of Directors as an independent director since July 2021. Kim has come out of retirement to lead Volcon's successful market launch of the Stag. Prior to joining Volcon's Board of Directors Mr. Kim was an accomplished serial entrepreneur, product designer and is currently a private investor. Mr. Kim was the CEO and founder of Super73.

07:09 EST Everbridge to be acquired by Thoma Bravo for $1.5B in cash - Everbridge announced that it has entered into a definitive agreement to be acquired by Thoma Bravo in an all-cash transaction valuing Everbridge at approximately $1.5B. Upon completion of the transaction, Everbridge will become a privately held company. Under the terms of the agreement, Everbridge shareholders will receive $28.60 per share in cash. The per share purchase price represents a 32% premium to the Everbridge volume-weighted average share price over the last 90 days. The transaction, which was approved by the Everbridge board of directors, is expected to close in the second calendar quarter of 2024, subject to customary closing conditions, including approval by Everbridge shareholders and the receipt of required regulatory approvals. The transaction is not subject to a financing condition. The agreement includes a 25-day "go-shop" period expiring on February 29, 2024, which permits the Everbridge Board and its advisors to actively initiate and solicit alternative acquisition proposals from certain third parties, as described in the merger agreement. The Everbridge board has the right to terminate the merger agreement to accept a superior proposal subject to the terms and conditions of the merger agreement. There can be no assurance that this "go-shop" will result in a superior proposal, and Everbridge does not intend to disclose developments with respect to the solicitation process unless and until it determines such disclosure is appropriate or otherwise required. Upon completion of the transaction, Everbridge common stock will no longer be listed on any public stock exchange. The company will continue to operate under the Everbridge name and brand.

07:08 EST Magnolia Oil & Gas announces 13% increase to quarterly dividend rate - Magnolia Oil & Gas announced that its Board of Directors has declared a cash dividend of 13c per share of Class A common stock, and a cash distribution of 13c per Class B unit, payable on March 1 to shareholders of record as of February 16. Today's announcement represents a 13% increase to Magnolia's quarterly dividend rate and would provide an annualized dividend of 52c per share. This is the third consecutive year that Magnolia has increased its dividend rate since initiating a dividend payment in 2021. Magnolia expects to declare its next quarterly dividend in May for payment in June. "The increase in the dividend is supported by our record of executing on our strategy and improving the business in 2023, during which Magnolia's total production grew 9% and our share repurchase activities reduced our outstanding shares 4%," said Chris Stavros, Magnolia's President and CEO. "Magnolia's principles of maintaining low leverage with disciplined capital spending, generating modest annual production growth and sustaining high pre-tax margins delivers steady and consistent free cash flow. This strategy improves Magnolia's dividend per share payout capacity, allowing for above average and consistent annual dividend growth that is superior to that of our peers. Importantly, Magnolia's dividend is secure at significantly lower product prices, which will appeal to long-term investors who value dividend safety through commodity cycles. Delivering a sustainable, safe and growing dividend is a key component of Magnolia's total shareholder return strategy."

07:08 EST Macerich announces Hsieh to become CEO when CEO O'Hern retires - The Macerich Company announced that Jackson Hsieh will become the President and Chief Executive Officer, CEO, of Macerich on March 1, 2024, following the retirement of Thomas O'Hern after 30 years of service to the Company. O'Hern will serve as an advisor to the Company through June 30, 2024, to ensure a smooth transition. Hsieh's appointment as President and Chief Executive Officer follows an extensive search process by the Board with the assistance of Ferguson Partners, a prominent global executive recruitment firm. Concurrent with O'Hern's retirement, President Edward Coppola will also be retiring from the Company.

07:06 EST Smart for Life selects SGS Nutrasource to support global strategic expansion - Smart for Life announced that it has selected SGS Nutrasource, a premier global contract research organization, CRO, to assist Smart for Life in the analysis of various regulatory, product development, and testing solutions for its products and dietary supplements, as Smart for Life accelerates its M&A activity. "The SGS Nutrasource services are a central component of our compliance strategy and our commitment to all current regulatory guidelines as we continue to expand our product lines through accretive acquisitions," stated Darren Minton, CEO of Smart for Life. "SGS Nutrasource has an impeccable reputation for excellence in science and regulation, not only in the U.S. and Canada, but globally. Having access to this industry-leading level of expertise allows us to differentiate our products, register new products in countries around the world where they specialize, in addition to driving value for shareholders as we embark on the next phase of our M&A strategy."

07:05 EST Lexeo Therapeutics announces new executive appointments - Lexeo Therapeutics announced new executive appointments to lead the evolution of the company's pipeline into late-stage clinical development. Sandi See Tai, MD, has been promoted to Chief Development Officer. Prior to Lexeo, Dr. See Tai was VP & Development Head for Rare Disease at Pfizer, responsible for setting the Rare Disease internal portfolio strategy and delivering its clinical development portfolio of investigational products and in-line assets. Eric Adler, MD, has been appointed Chief Medical Officer & Head of Research. As a pioneer and thought leader in cardiovascular gene therapy, Dr. Adler formerly served as Chief Scientific Officer at Lexeo since joining in 2022. Rajiv Patni, MD, has been appointed Senior Advisor to the CEO and Board of Directors of Lexeo. Dr. Patni was formerly Chief Research and Development Officer at Reata Pharmaceuticals Jenny R. Robertson has been appointed Chief Business and Legal Officer. Ms. Robertson formerly served as Chief Legal and Administrative Officer at Lexeo, leading legal, human resources, information technology, information security, and facilities strategies and activities. Prior to Lexeo, Ms. Robertson served as Chief Counsel to Pfizer's Oncology Business.

07:04 EST McDonald's reports Q4 global SSS up 3.4%, U.S. SSS up 4.3% - Fourth quarter financial performance: Global comparable sales increased 3.4%, reflecting positive comparable sales across all segments. U.S. increased 4.3%. International Operated Markets segment increased 4.4%. International Developmental Licensed Markets segment increased 0.7%, reflecting the impact of the war in the Middle East. Consolidated revenues increased 8% (6% in constant currencies). Systemwide sales increased 6% (5% in constant currencies).

07:04 EST NRx Pharmaceuticals announces incorporation of Hope Therapeutics - NRx Pharmaceuticals announced the incorporation of Hope Therapeutics, a biotechnology company dedicated to bringing NRX-100, or IV Ketamine, which will be re-designated HTX-100, a potentially lifesaving treatment option for patients with Suicidal Depression. The company will initially be owned by NRx and its current shareholders, who will receive their shares in the form of a dividend with an accompanying royalty coupon tied to future sales of HTX-100, subject to board approval. This is designed with counsel to not be a taxable event for shareholders. Hope is dedicated to providing an FDA-approved presentation of IV Ketamine, manufactured to current federal standards, in a diversion- and abuse-deterrent presentation. A new drug application, or NDA, is planned for the first half of 2024, based on more than 1,000 patients treated in well-controlled trials of ketamine in Suicidal Depression together with HOPE's expertise in sterile products formulation. Importantly, the company intends to provide patient and reimbursement support for all of its patients and their clinics. NRx also expects to convene a shareholder meeting in the coming weeks to vote on the planned structure of the spin-out of Hope Therapeutics and the stock dividend. The company further announces cancellation of the previously announced February 7 shareholder meeting to approve the option of a reverse stock split to maintain Nasdaq compliance; this will be rescheduled, if necessary.

07:02 EST Brookfield announces $10B closing for second Global Transition Fund - Brookfield Asset Management has raised $10 billion in the first closing of the second Brookfield Global Transition Fund, inclusive of fund commitments and strategic capital from our investor base. The Fund continues to see significant support from both existing and new investors, cementing Brookfield's position as the world's largest transition investor among private fund managers. BGTF II is co-headed by Mark Carney and Connor Teskey and focuses on investments to accelerate the global transition to a net zero economy while delivering strong risk-adjusted returns for investors. The Fund continues the predecessor fund strategy of investing in the expansion of clean energy, the acceleration of sustainable solutions, and the transformation of companies operating in carbon-intensive sectors to more sustainable business models. The Fund's seed portfolio includes a UK onshore renewables developer and a solar development partnership in India, and the pipeline of further investment opportunities is robust. Brookfield is targeting a larger fundraise for BGTF II than its predecessor fund and continues to see a significant acceleration in transition opportunities globally. The Fund is the successor of the inaugural Brookfield Global Transition Fund which closed on a record $15 billion, inclusive of fund commitments and strategic capital from our investor base in June 2022, making it the largest such fund in the world. The capital in BGTF I is now substantially deployed or committed to a range of landmark investments across renewable power, business transformation, carbon capture and storage, renewable natural gas, and nuclear services opportunities. All investments are managed to science-based sector pathways for net zero and the total impact of BGTF I, measured in avoided emissions, is on track to exceed the combined annual emissions of New York City, London and Toronto. Fundraising for BGTF II is expected to conclude in Q3 of this year.

06:59 EST Everbridge halted, news pending

06:51 EST Estee Lauder announces restructuring plan, 3%-5% headcount reduction - The company announced it is further expanding its Profit Recovery Plan for fiscal years 2025 and 2026 to include a restructuring program. The now-larger overall plan is focused on rebuilding stronger, more sustainable profitability, supporting sales growth acceleration and increasing speed and agility. The plan is designed to improve gross margin, lower the cost base and reduce overhead expenses, while increasing investments in key consumer-facing activities. Upon completion of this plan, the Company expects to have improved its gross margin and expense base to drive greater operating leverage for the future. The restructuring program will begin during the Company's fiscal 2024 third quarter. Specific initiatives under this restructuring program are expected to be substantially completed by the end of fiscal 2026. The restructuring program's main focus includes the reorganization and rightsizing of certain areas of the Company as well as simplification and acceleration of processes. In connection with the restructuring program, at this time the Company estimates a net reduction in the range of approximately 3-5% of its positions as of June 30, 2023. This reduction takes into account the elimination of some positions as well as retraining and redeployment of certain employees in select areas. Once fully implemented, the Company expects to take restructuring and other charges of between $500 million and $700 million, before taxes, consisting of employee-related costs, contract terminations, asset write-offs and other costs associated with implementing these initiatives. The program is expected to yield annual gross benefits of between $350 million and $500 million, before taxes, of which a portion is expected to be reinvested in consumer facing areas to drive sustainable, profitable growth. The Company now expects to drive incremental operating profit through the initiatives in the Profit Recovery Plan of $1.1 billion to $1.4 billion, including net benefits from the restructuring program. This is an increase from the $800 million to $1 billion previously communicated. The plan is anticipated to enable the realization of nearly all of the expected benefits in fiscal years 2025 and 2026, more than half of which is expected to benefit fiscal 2025 operating profitability. The Company remains optimistic about the long-term prospects and future growth opportunities in global prestige beauty. As part of this plan, the Company expects to increase its investments in the strong equity and desirability of its brands to drive sustainable growth, and believes it is well-positioned to drive better diversified growth across its portfolio. The Company continues to monitor the effects of the global macro environment, including the risk of recession; currency volatility; inflationary pressures; supply chain challenges; social and political issues; regulatory matters, including the imposition of tariffs and sanctions; geopolitical tensions; and global security issues. The Company is also mindful of inflationary pressures on its cost base and is monitoring the impact on consumer preferences.

06:46 EST Estee Lauder announces restructuring plan

06:39 EST Ault Inc.'s Sentium announces 121 Bitcoin mined in January 2024 - Ault Alliance announced that its wholly owned subsidiary, Sentinum, mined approximately 121 Bitcoin in January 2024. Of this total, approximately 65 Bitcoin were mined at Sentinum's data center in Michigan, with the remaining approximately 56 Bitcoin from mining machines hosted with Core Scientific. The January mining operations represent a current Bitcoin mining operations annual run rate of approximately $62M worth of Bitcoin. The mining run rate is based upon a current Bitcoin price of approximately $42,700.

06:39 EST Hamilton Beach acquires HealthBeacon, terms undisclosed - Hamilton Beach announced that through its Hamilton Beach Health subsidiary it has acquired HealthBeacon, a medical technology firm and strategic partner of the company. HealthBeacon develops connected devices that enable patients with chronic conditions to manage their injectable medication regimens at home and provides other health services. HealthBeacon operates in the United Kingdom, Europe, North America, and Australia. Its revenue model is subscription based. HealthBeacon has approximately 50 employees, including engineers, data scientists, software developers, technicians, designers and customer care representatives, and has obtained more than 30 design and utility patents. HealthBeacon was founded in 2013 in Dublin, Ireland.

06:37 EST Westwater Resources signs first agreement for graphite sale from Kellyton Plant - Westwater Resources announced the execution of its first off-take agreement with SK On, an electric vehicle battery manufacturer, supplying electric vehicle batteries to Ford, Hyundai, Volkswagen and others. Westwater will supply CSPG-10 natural graphite anode products from its Kellyton Graphite Plant located near Kellyton, Alabama to SK On battery plants located within the U.S. Under the terms of the Procurement Agreement, SK On will be obligated to purchase, on an annual basis, a quantity of Product equal to a percentage of the forecasted volume required by SK On, provided that the Minimum Purchase Amount may be increased from time to time by the mutual agreement of the parties. The forecasted volume required by SK On in the final year of the Off-Take Agreement is 10,000 mt of Product.

06:26 EST Catalent jumps 13% to $61.46 after Novo Holdings merger agreement

06:05 EST HighPeak Energy raises dividend 60%, announces $75M share repurchase plan - HighPeak Energy announced a 60% increase to its quarterly dividend to 4c per share and a $75M share repurchase authorization. The company's Board of Directors declared a quarterly dividend of 4c per share to be paid on March 25 to stockholders of record on March 1.

06:03 EST Yandex selling Russian operations for RUB 475B - Yandex N.V., the Dutch parent company of the Yandex group, announces that it has entered into a definitive agreement with a purchaser consortium to sell all of the Yandex group's businesses in Russia and certain international markets. The total consideration for the sale will be RUB 475B, subject to adjustments and payable in a combination of cash and Class A shares of YNV. At least 50% of the consideration will be paid in cash. The proposed sale will be presented for approval at a meeting of the Class A Shareholders and a separate Extraordinary General Meeting of Shareholders. YNV will provide a notice of the meetings, together with a detailed shareholder circular outlining the terms and background to the transaction, in the coming days. "Since February 2022, the Yandex group and our team have faced exceptional challenges. We believe that we have found the best possible solution for our shareholders, our teams and our users in these extraordinary circumstances," said John Boynton, Chairman of the Board of Directors of Yandex N.V. "The proposed transaction will allow shareholders to recover some value for the businesses that we are divesting, while unlocking new growth potential for the international businesses we will retain and enabling the divested businesses to operate under new ownership. Yandex is a unique story. I am proud to have been a part of that story since the very beginning, and I am proud to be part of the next chapter. We believe that the proposed sale will position both parts of the current group to develop and grow for the benefit of their stakeholders." As announced in November 2022, YNV's Board of Directors undertook a strategic process to review options to restructure the group's ownership and governance in light of the unprecedented and exceptional geopolitical environment. Reference Link

05:35 EST Nutex Health doubles Medicare Advantage membership during 2023 enrollment period - Nutex Health announced that it has more than doubled its Medicare Advantage membership during the 2023 annual enrollment period from October to December 2023. In Texas, Houston Physicians IPA, or HPIPA, enrolled over 1900 new Medicare Advantage, or MA, patients. In Florida, Managed Care Insurance Consultants, or MCIC, enrolled over 200 new MA patients, and in California, Associated Hispanic Physicians IPA, or AHP, enrolled 300 new MA members. In total, Nutex Health now has over 4500 MA members across its platform, in addition to over 6300 commercial members and over 21,000 Medicaid managed care members.

05:16 EST Nokia signs multi-year patent cross-license agreement with vivo - Nokia announced it has signed a multi-year patent cross-license agreement with vivo. Under the agreement vivo will make royalty payments to Nokia, along with catch-up payments to cover the dispute period. The agreement resolves all pending patent litigation between the parties, in all jurisdictions. The terms of the agreement remain confidential as agreed between the parties. The agreement is consistent with the assumptions that Nokia has disclosed for Nokia Technologies in its financial report for Q4 issued on January 25. Nokia will begin recognizing net sales from this agreement, including catch up payments covering the periods of non-payment, in Q1. Nokia Technologies is progressing towards the conclusion of the smartphone licensing renewal cycle and is making good progress in its growth areas of automotive, consumer electronics, IoT and multimedia. It remains confident that its annual net sales run-rate will return to EUR 1.4B to EUR 1.5B in the mid-term. Nokia's patent portfolio is built on around EUR 150B invested in R&D since 2000 and is composed of around 20,000 patent families, including over 6,000 patent families declared essential to 5G. Nokia contributes its inventions to open standards in return for the right to license them on fair, reasonable and non-discriminatory terms. Companies can license and use these technologies without the need to make their own substantial investments in the standards, fueling innovation and the development of new products and services for consumers.

05:12 EST Kraft Heinz signs agreement with Carlton Power for green hydrogen project in UK - Kraft Heinz has signed an agreement with Carlton Power, the UK energy infrastructure development company, to study the development of a renewable green hydrogen plant at its Kitt Green manufacturing plant in Wigan, Greater Manchester. Kitt Green is one of the largest food processing plants in Europe and one of the largest Kraft Heinz facilities in the world, producing a quarter of a million tons of food annually and employing approximately 850 people. The proposed 20MW Kitt Green hydrogen plant, the first to be taken forward by Kraft Heinz globally, will meet more than 50% of the plant's annual natural gas demand and reduce the plant's carbon emissions by 16000T/yr. The hydrogen will be produced by an electrolyzer using electricity generated from sources of renewable energy, primarily wind and solar power. The Kitt Green project is the fifth green hydrogen project that Carlton Power is taking forward within the UK.